LINFOMAS Y TRASPLANTES
University Medical Center Hamburg-Eppendorf
Hamburgo, AlemaniaPublicaciones en colaboración con investigadores/as de University Medical Center Hamburg-Eppendorf (17)
2024
-
Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
Transplantation and Cellular Therapy, Vol. 30, Núm. 1, pp. 93.e1-93.e12
-
Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study
Bone Marrow Transplantation, Vol. 59, Núm. 5, pp. 604-614
2023
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
Haematologica
-
Severe cytopenia after CD19 CAR T-cell therapy: A retrospective study from the EBMT Transplant Complications Working Party
Journal for ImmunoTherapy of Cancer, Vol. 11, Núm. 4
2022
-
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
Blood Cancer Journal, Vol. 12, Núm. 9
-
Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT
Bone Marrow Transplantation
2021
-
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Leukemia, Vol. 35, Núm. 10, pp. 2885-2894
-
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Leukemia, Vol. 35, Núm. 12, pp. 3585-3588
-
Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT
Bone Marrow Transplantation, Vol. 56, Núm. 2, pp. 481-491
2019
-
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
Haematologica, Vol. 104, Núm. 5, pp. 929-936
2017
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
2015
-
Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma
Bone Marrow Transplantation, Vol. 50, Núm. 6, pp. 802-807
2005
2004
-
Lenograstim after autologous peripheral blood progenitor cell transplantation: Results of a double-blind, randomized trial
Bone Marrow Transplantation, Vol. 34, Núm. 11, pp. 955-962
2003
-
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow
Blood, Vol. 102, Núm. 8, pp. 3043-3051
-
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning
Leukemia, Vol. 17, Núm. 5, pp. 841-848
2002
-
Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia
Blood, Vol. 100, Núm. 12, pp. 3877-3886